Literature DB >> 31276577

Differential Effects of Rapamycin on Glucose Metabolism in Nine Inbred Strains.

Peter C Reifsnyder1, Austen Te1, David E Harrison1.   

Abstract

Studies in mice suggest that rapamycin has a negative impact on glucose homeostasis by inducing insulin resistance. However, results have been inconsistent and difficult to assess because the strains, methods of treatment, and analysis vary among studies. Using a consistent protocol, we surveyed nine inbred strains of mice for the effect of rapamycin on various aspects of glucose metabolism. Across all strains, rapamycin significantly delayed glucose clearance after challenge. However, rapamycin showed no main effect on systemic insulin sensitivity. Analysis of individual strains shows that rapamycin induced higher glucose values at 15 minutes post-challenge in 7/9 strains. However, only three strains show rapamycin-induced reduction in glucose clearance from 15 to 120 minutes. Although pancreatic insulin content was reduced by rapamycin in seven strains, none showed reduced serum insulin values. Although one strain showed no effects of rapamycin on glucose metabolism (129), another showed increased systemic insulin sensitivity (B6). We suggest that rapamycin likely inhibits insulin production and secretion in most strains while having strain-specific effects on glucose clearance without altering systemic insulin sensitivity. This strain survey indicates that genetic differences greatly influence the metabolic response to rapamycin.
© The Author(s) 2019. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Glucose tolerance; Insulin sensitivity; Pharmacogenetics

Year:  2020        PMID: 31276577      PMCID: PMC6909913          DOI: 10.1093/gerona/glz157

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  23 in total

1.  Genetics: influence of TOR kinase on lifespan in C. elegans.

Authors:  Tibor Vellai; Krisztina Takacs-Vellai; Yue Zhang; Attila L Kovacs; László Orosz; Fritz Müller
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

2.  Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice.

Authors:  Richard A Miller; David E Harrison; C M Astle; Joseph A Baur; Angela Rodriguez Boyd; Rafael de Cabo; Elizabeth Fernandez; Kevin Flurkey; Martin A Javors; James F Nelson; Carlos J Orihuela; Scott Pletcher; Zelton Dave Sharp; David Sinclair; Joseph W Starnes; J Erby Wilkinson; Nancy L Nadon; Randy Strong
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-10-25       Impact factor: 6.053

3.  Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients.

Authors:  Matt Kaeberlein; R Wilson Powers; Kristan K Steffen; Eric A Westman; Di Hu; Nick Dang; Emily O Kerr; Kathryn T Kirkland; Stanley Fields; Brian K Kennedy
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

4.  Rapamycin Modulates Markers of Mitochondrial Biogenesis and Fatty Acid Oxidation in the Adipose Tissue of db/db Mice.

Authors:  Sathyaseelan S Deepa; Michael E Walsh; Ryan T Hamilton; Daniel Pulliam; Yun Shi; Shauna Hill; Yan Li; Holly Van Remmen
Journal:  J Biochem Pharmacol Res       Date:  2013-06

5.  The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span.

Authors:  Kailiang Jia; Di Chen; Donald L Riddle
Journal:  Development       Date:  2004-07-14       Impact factor: 6.868

6.  Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway.

Authors:  Pankaj Kapahi; Brian M Zid; Tony Harper; Daniel Koslover; Viveca Sapin; Seymour Benzer
Journal:  Curr Biol       Date:  2004-05-25       Impact factor: 10.834

7.  Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression.

Authors:  Anindita Das; David Durrant; Saisudha Koka; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  J Biol Chem       Date:  2013-12-26       Impact factor: 5.157

8.  Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice.

Authors:  Kassem Makki; Solenne Taront; Olivier Molendi-Coste; Emmanuel Bouchaert; Bernadette Neve; Elodie Eury; Stéphane Lobbens; Myriam Labalette; Hélène Duez; Bart Staels; David Dombrowicz; Philippe Froguel; Isabelle Wolowczuk
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

9.  Rapamycin-induced metabolic defects are reversible in both lean and obese mice.

Authors:  Yuhong Liu; Vivian Diaz; Elizabeth Fernandez; Randy Strong; Lan Ye; Joseph A Baur; Dudley W Lamming; Arlan Richardson; Adam B Salmon
Journal:  Aging (Albany NY)       Date:  2014-09       Impact factor: 5.682

10.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Authors:  David E Harrison; Randy Strong; Zelton Dave Sharp; James F Nelson; Clinton M Astle; Kevin Flurkey; Nancy L Nadon; J Erby Wilkinson; Krystyna Frenkel; Christy S Carter; Marco Pahor; Martin A Javors; Elizabeth Fernandez; Richard A Miller
Journal:  Nature       Date:  2009-07-08       Impact factor: 49.962

View more
  3 in total

1.  TORwards a Victory Over Aging.

Authors:  Dudley W Lamming; Adam B Salmon
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-01-01       Impact factor: 6.591

Review 2.  Preclinical models versus clinical renal ischemia reperfusion injury: A systematic review based on metabolic signatures.

Authors:  Lente J S Lerink; Michèle J C de Kok; John F Mulvey; Sylvia E Le Dévédec; Alexander A Markovski; Rob C I Wüst; Ian P J Alwayn; Rutger J Ploeg; Alexander F M Schaapherder; Jaap A Bakker; Jan H N Lindeman
Journal:  Am J Transplant       Date:  2021-11-01       Impact factor: 9.369

3.  Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice.

Authors:  Peter C Reifsnyder; Kevin Flurkey; Rosalinda Doty; Nigel A Calcutt; Robert A Koza; David E Harrison
Journal:  Aging Cell       Date:  2022-08-19       Impact factor: 11.005

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.